NEWS
Our venture capital funds focus on promising technologies that have made positive impacts across the globe.
April 8, 2024
MMI Receives FDA Authorization to Commercialize Symani Surgical System in the U.S.
March 6, 2024
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
February 29, 2024
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
February 27, 2024
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System
February 27, 2024
Foldax, Inc. Signs Manufacturing Agreement with Dolphin Life Science India LLP to Expedite Upcoming Commercial Availability
January 12, 2024
Mark Toland, BioStar Managing Director: Medical Innovation Must Shift Focus From Common Problems to Unsolvable Ones
December 6, 2023
BioStar Capital Closes Fund V at $130.3 Million, Surpassing Previous Funds
April 18, 2023
2023 Midwest Growth Capital Symposium to Feature Louis Cannon and Dug Song as Keynotes
April 4, 2023
AVS’s Pulsatile Intravascular Lithotripsy Technology Attracts an Additional $8.8M to Close $28.8M Series B Round
March 16, 2023
BioStar Capital, Top 20 Venture Capital Firm 2023: Fueling Medtech Innovations with Uncompromised Fund Performance (Financial Services Review)
January 17, 2023
BioStar Capital in The Wall Street Journal: Venture Interest in Medical Devices Holds Up, but Investors Are Choosy
January 5, 2023
AVS Raises $20 Million in Series B Round to Advance Pulsatile Intravascular Lithotripsy (PIVL) Solutions
September 15, 2022
AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors
September 13, 2022
MedTech Strategist Article: Foldax advances the Next Big Thing in Heart Valves: Robotic Manufacturing
July 27, 2022
Medtech Money Podcast, Episode 85: Louis Cannon, Founder & Senior Managing Director at BioStar Capital
June 17, 2022
Senseonics lands CE mark for 6-month CGM implant, teeing up Q3 launch in Europe
June 13, 2022
Ablative Solutions, Inc. Announces Completion of the Fourth Tranche of its Series D Preferred Financing Round for Unique Therapeutic Approach to Treating Uncontrolled Hypertension
May 24, 2022
REVA Medical announces final 5 year results for its FANTOM II coronary scaffold study
May 3, 2022
First Patients Outside of U.S. Treated with TRIA Biopolymer Surgical Aortic Heart Valve in India Clinical Trial
March 30, 2022
Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Device, Expanded Patent Portfolio, and Further Clinical Studies
January 5, 2022
Senseonics expects FDA approval for next-gen 180-day CGM in ‘coming weeks’